CoChat

Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials

Open access

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Abstract

Asian patients with type 2 diabetes (T2D) are younger, leaner, and more likely to develop renal dysfunction than White populations. In this multiethnic analysis of data from phase 3 trials, we investigated the efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in Asians stratified by these subphenotypes. Data from randomized, double-blind, placebo-controlled trials evaluating linagliptin (as monotherapy, add-on therapy to metformin ± sulfonylurea, combined with pioglitazone or added to insulin) were pooled with efficacy data from 11 randomized trials of at least 24 weeks and safety data from 15 trials of various durations. In the efficacy set, 1404 Asian patients received linagliptin [mean (standard deviation) age 54.5 (10.1) years; body mass index (BMI) 26.0 (3.9) kg/m 2 ] and 661 received placebo [age 55.0 (9.7) years; BMI 26.1 (3.9) kg/m 2 ] with the same glycated hemoglobin (HbA1c): 8.2 (0.9)% in both groups. At 24 weeks, the placebo-corrected adjusted mean ± standard error change from baseline in HbA1c with linagliptin was −0.73 ± 0.04% (95% confidence interval −0.81, −0.65; P < 0.0001). Reductions in HbA1c were similar upon stratification by age [<65 years, −0.71 ± 0.05% (−0.80, −0.62; P < 0.0001); ≥65 years, −0.81 ± 0.10% (−1.01, −0.60; P < 0.0001)], BMI (<25 kg/m 2 , −0.82 ± 0.06% [−0.94, −0.70; P < 0.0001]; ≥25 kg/m 2 , −0.65 ± 0.06% [−0.76, −0.54; P < 0.0001]) and estimated glomerular filtration rate [<90 mL/min/1.73 m 2 , −0.71 ± 0.06% (−0.82, −0.60; P < 0.0001); ≥90 mL/min/1.73 m 2 , −0.75 ± 0.06% (−0.87, −0.64; P < 0.0001)]. In the safety set (linagliptin, n = 1842; placebo, n = 839), 52.2% and 54.6% of patients, respectively, experienced adverse events. The rates of drug-related adverse events were 10.9% in the linagliptin group and 10.4% in the placebo group. The respective rates of hypoglycemia were 8.3% and 9.5%, mainly among patients treated with sulfonylurea or insulin. Severe hypoglycemia was rare (<1.0% in either group). Linagliptin effectively reduced hyperglycemia in Asian patients with uncontrolled T2D, irrespective of age, BMI, renal function, or ethnic subgroups, and was well tolerated. Boehringer Ingelheim, Eli Lilly and Company, and the Diabetes Alliance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-017-0595-7

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 a Placebo-corrected adjusted mean change in HbA1c with linagliptin in regional subpopulations*. Adjusted mean change in HbA1c b by BMI subgroup, c age, d by eGFR (all data are FAS-LOCF). BMI body mass index, CI confidence interval, eGFR estimated glomerular filtration rate, FAS full analysis set, HbA1c glycated hemoglobin, LOCF last observation carried forward, SE standard error, SD standard deviation. *East Asians: China, Korea, Taiwan, Hong Kong, and Japan; Southeast Asians: Indonesia, Malaysia, Philippines, Singapore, and Thailand; South Asians: India
Fig. 1 a Placebo-corrected adjusted mean change in HbA1c with linagliptin in regional subpopulations*. Adjusted mean change in HbA1c b by BMI subgroup, c age, d by eGFR (all data are FAS-LOCF). BMI body mass index, CI confidence interval, eGFR estimated glomerular filtration rate, FAS full analysis set, HbA1c glycated hemoglobin, LOCF last observation carried forward, SE standard error, SD standard deviation. *East Asians: China, Korea, Taiwan, Hong Kong, and Japan; Southeast Asians: Indonesia, Malaysia, Philippines, Singapore, and Thailand; South Asians: IndiaCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 2

  1. American Diabetes Association. Standards of medical care in diabetes—2015: summary of revisions. Diabetes Care. 2015;38(Suppl):S4.
  2. Bajaj M, Gilman R, Patel S, Kempthorne-Rawson J, Woerle HJ. Linagliptin improved glycemic control without weight gain or hypoglycemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone. Diabetes. 2013;62(Suppl 1):A283.

Cited by

See all 13

Metadata

Authors
Ning, G., Bandgar, T., Hehnke, U., Lee, J., & Chan, J. C. N.
Affiliations
  • King Edward Memorial Hospital and Seth G.S. Medical College (IN)
  • Boehringer Ingelheim (Germany) (DE)
  • Chinese University of Hong Kong (HK)
Corresponding author
Ning, Guang
Venue
Advances in Therapy
Published
2017-08-17
Volume
34
Issue
9
Pages
2150-2162
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W2750537112
Cited by
13
References
48
Citations by year
2025: 1 · 2023: 2 · 2022: 4 · 2021: 2 · 2020: 3 · 2019: 1
FWCI
0.86
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Advances in Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • Diabetes Alliance
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
linagliptin, type 2 diabetes, DPP-4 inhibitors, Asian patients, age, obesity, renal function, HbA1c reduction, glycemic control, renal safety, drug safety, metformin, sulfonylureas, pioglitazone, insulin, subgroup analysis, pooled analysis of trials, renal dysfunction, older adults, body mass index
MeSH terms
Linagliptin, Adult, Age Factors, Aged, Aged, 80 and over, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Asian People, Renal Insufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials. https://app.cochat.ai/papers/10.1007/s12325-017-0595-7
The paper
Ning, G., Bandgar, T., Hehnke, U., Lee, J., & Chan, J. C. N. (2017). Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials. Advances in Therapy. https://doi.org/10.1007/s12325-017-0595-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.